| Literature DB >> 35664877 |
Stephanie Coupal1, Kenneth Lukas1, Amy Plint2, Maala Bhatt2, Kevin Cheung3, Kevin Smit1, Sasha Carsen1.
Abstract
Purpose: Gartland Type 1 supracondylar humerus fractures are stable, non-displaced injuries treated with non-operative management. This systematic review was performed to gather evidence on the optimal form of immobilization to treat these fractures.Entities:
Keywords: cast; pediatrics; splint; supracondylar humerus fractures; systematic review
Year: 2022 PMID: 35664877 PMCID: PMC9160664 DOI: 10.3389/fped.2022.863985
Source DB: PubMed Journal: Front Pediatr ISSN: 2296-2360 Impact factor: 3.569
FIGURE 1Prisma diagram.
Description of studies that met the inclusion criteria and included clinical outcome data.
| Author, Year | Design | Location | Type of immobilization | Duration of immobilization | Outcomes reported | Age: Mean (range) in years | Number of participants |
| Leksan et al. ( | Prospective Cohort | Europe | Humerus splint, cast, and Blount’s immobilization | Not reported | 1. ROM | Not reported | 38 |
| Ballal et al. ( | Quasi-experimental | Europe | A. Cuff and Collar | Not reported. Patients evaluated 2.67 days from injury (range 1-8 days) and then followed clinically | 2. Fracture displacement (no formal radiographic follow-up) | A. 6 | A. 20 |
| Oakley et al. ( | RCT | Australia | A. Collar and Cuff | 14–16 days, plus 2 additional weeks if tenderness/discomfort remained | 1. Fracture displacement | A. 5.2 | A. 23 |
| Silva et al. ( | RCT | North America | A. Long Arm Cast (Traditional Hard Fiberglass) with sling | 4 weeks | 1. Fracture displacement | A. 4.8 | A. 50 |
| Silva et al. ( | RCT | North America | A. Long Arm Cast (Soft fiberglass) | 4 weeks | 1. Fracture displacement | A. 5 | A. 26 |
Risk of bias for prospective cohort studies - Newcastle–Ottawa score.
| Study | Selection | Comparability | Outcome |
| Leksan et al. ( | 0 | 0 | * |
Risk of bias for randomized control trials (RCTs) (ROB-2) and non-RCTs (ROBINS-1).
| Study | Experimental | Comparator | Primary outcome | Risk of bias tool used | Randomization process | Confounding | Selection of participipants | Classification of interventions | Deviations from intended interventions | Missing outcome data | Measurement of the outcome | Selection of the reported result/outcome | Overall |
| Oakley et al. ( | Cuff and Collar | Backslab | Fracture displacement | ROB-2 |
| N/A | N/A | N/A |
|
|
|
| |
| Silva et al. ( | Long arm cast (hard Fiberglass) | Long arm cast (soft Fiberglass) | Fracture displacement | ROB-2 |
| N/A | N/A | N/A |
|
|
|
| |
| Silva et al. ( | Long arm cast (soft Fiberglass) | Long arm cast (soft Fiberglass) | Fracture displacement | ROB-2 |
| N/A | N/A | N/A |
|
|
|
| |
| Ballal et al. ( | Backslab | Cuff and Collar | Fracture Displacement | ROBINS-1 | N/A |
|
|
|
|
|
|
|
Legend:
| Section/topic | # | Checklist item | Reported on page # |
|
| |||
| Title | 1 | Identify the report as a systematic review, meta-analysis, or both. | Title Page |
|
| |||
| Structured summary | 2 | Provide a structured summary including, as applicable: background; objectives; data sources; study eligibility criteria, participants, and interventions; study appraisal and synthesis methods; results; limitations; conclusions and implications of key findings; systematic review registration number. | 1–2 |
|
| |||
| Rationale | 3 | Describe the rationale for the review in the context of what is already known. | 3 |
| Objectives | 4 | Provide an explicit statement of questions being addressed with reference to participants, interventions, comparisons, outcomes, and study design (PICOS). | 3 |
|
| |||
| Protocol and registration | 5 | Indicate if a review protocol exists, if and where it can be accessed (e.g., Web address), and, if available, provide registration information including registration number. | 4 |
| Eligibility criteria | 6 | Specify study characteristics (e.g., PICOS, length of follow-up) and report characteristics (e.g., years considered, language, publication status) used as criteria for eligibility, giving rationale. | 4 |
| Information sources | 7 | Describe all information sources (e.g., databases with dates of coverage, contact with study authors to identify additional studies) in the search and date last searched. | 4 |
| Search | 8 | Present full electronic search strategy for at least one database, including any limits used, such that it could be repeated. | Appendix |
| Study selection | 9 | State the process for selecting studies (i.e., screening, eligibility, included in systematic review, and, if applicable, included in the meta-analysis). | 4–5 |
| Data collection process | 10 | Describe method of data extraction from reports (e.g., piloted forms, independently, in duplicate) and any processes for obtaining and confirming data from investigators. | 5–6 |
| Data items | 11 | List and define all variables for which data were sought (e.g., PICOS, funding sources) and any assumptions and simplifications made. | 5–6 |
| Risk of bias in individual studies | 12 | Describe methods used for assessing risk of bias of individual studies (including specification of whether this was done at the study or outcome level), and how this information is to be used in any data synthesis. | 6 ( |
| Summary measures | 13 | State the principal summary measures (e.g., risk ratio, difference in means). | N/A (descriptive analysis only due to heterogenous studies) |
| Synthesis of results | 14 | Describe the methods of handling data and combining results of studies, if done, including measures of consistency (e.g., I2) for each meta-analysis. | N/A |
| Risk of bias across studies | 15 | Specify any assessment of risk of bias that may affect the cumulative evidence (e.g., publication bias, selective reporting within studies). | 6 |
| Additional analyses | 16 | Describe methods of additional analyses (e.g., sensitivity or subgroup analyses, meta-regression), if done, indicating which were pre-specified. | N/A |
|
| |||
| Study selection | 17 | Give numbers of studies screened, assessed for eligibility, and included in the review, with reasons for exclusions at each stage, ideally with a flow diagram. |
|
| Study characteristics | 18 | For each study, present characteristics for which data were extracted (e.g., study size, PICOS, follow-up period) and provide the citations. |
|
| Risk of bias within studies | 19 | Present data on risk of bias of each study and, if available, any outcome level assessment (see item 12). | |
| Results of individual studies | 20 | For all outcomes considered (benefits or harms), present, for each study: (a) simple summary data for each intervention group (b) effect estimates and confidence intervals, ideally with a forest plot. | a) 7–11 |
| Synthesis of results | 21 | Present results of each meta-analysis done, including confidence intervals and measures of consistency. | N/A |
| Risk of bias across studies | 22 | Present results of any assessment of risk of bias across studies (see Item 15). | 6 (N/A) |
| Additional analysis | 23 | Give results of additional analyses, if done (e.g., sensitivity or subgroup analyses, meta-regression [see Item 16]). | N/A |
|
| |||
| Summary of evidence | 24 | Summarize the main findings including the strength of evidence for each main outcome; consider their relevance to key groups (e.g., healthcare providers, users, and policy makers). | 12–15 |
| Limitations | 25 | Discuss limitations at study and outcome level (e.g., risk of bias), and at review-level (e.g., incomplete retrieval of identified research, reporting bias). | 14–15 |
| Conclusions | 26 | Provide a general interpretation of the results in the context of other evidence, and implications for future research. | 15 |
|
| |||
| Funding | 27 | Describe sources of funding for the systematic review and other support (e.g., supply of data); role of funders for the systematic review. | N/A |
From: Moher D, Liberati A, Tetzlaff J, Altman DG, The PRISMA Group (2009). Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement. PLoS Med 6(7): e1000097. doi: 10.1371/journal.pmed1000097.
For more information, visit: